Efficacy Study of the Effect of Budesonide on Emphysema
This study has been completed.
Information provided by:
First received: October 4, 2005
Last updated: January 21, 2011
Last verified: January 2011
To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.
Chronic Obstructive Pulmonary Disease
Drug: Pulmicort (budesonide) Turbuhaler
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||The Effect of Inhaled Corticosteroids on the Development of Emphysema in Smokers Assessed by Computed Tomography (CT).|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- The primary variable in the study was change in lung density measured by Computed Tomography annually.
Secondary Outcome Measures:
- Decline in lung Function (FEV1) and exacerbation rate were measured biannually and decline in diffusion capacity (TLCO) annually.
|Study Start Date:||July 1999|
|Study Completion Date:||February 2004|
Contacts and Locations